Recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia

Medical Oncology

Volumn 15, Issue 3, 1998, Pages 141-144

  Nowrousian, Mr ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

anemia; chemotherapy; erythropoietin; quality of life; transfusion

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; EDITORIAL; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEMATOCRIT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; RETICULOCYTE COUNT; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSFERRIN BLOOD LEVEL;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEOPLASMS;

EID: 0031788988     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/BF02821932     Document Type: Editorial

References (32)

1. Skillings JRet al. The frequency of red cell transfusion for anaemia in patients receiving chemotherapy. A retrospective cohort study.Am J Clin Oncol 1993;16: 22–25. DOI: 10.1097/00000421-199302000-00006
2. Skillings JRet al. An epidemiological review of anaemia in cancer chemotherapy in Canada.Eur J Cancer 1995;31A (Suppl 5): S183.
3. Abels Ret al. Transfusion practice in advanced cancer patients.Blood 1991;78 (Suppl 1): 474a.
4. Nowrousian MRet al. Pathophysiology of cancer-related anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM (eds).rhErythropoietin in Cancer Supportive Treatment, Marcel Dekker: New York, 1996, pp. 13–34.
5. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy.Transfusion 1995;35: 427–430. DOI: 10.1046/j.1537-2995.1995.35595259154.x
6. Menitove JE. Transfusion-transmitted infections: Update.Semin Hematol 1996;33: 290–301.
7. Blumberg N. Allogeneic transfusion and infection: Economic and clinical implications.Semin Hematol 1997;34 (Suppl 2): 34–40.
8. Blumberg N, Heal JM. The transfusion immunomodulation theory: The Th1/Th2 paradigm and an analogy with pregnancy as a unifying mechanism.Semin Hematol 1996;33: 329–340.
9. Overgaard Jet al. Primary radiotherapy of larynx and pharynx carcinoma-An analysis of some factors influencing local control and survival.Int J Radiat Oncol Biol Phys 1986;12: 515–521.
10. Hirst DG. Anemia: A problem or an opportunity in radiotherapy.Int J Radiat Oncol Biol Phys 1986;12: 2009–2017.
11. Bush RS. The significance of anemia in clinical radiation therapy.Int J Radiat Oncol Biol Phys 1986;12: 2047–2050.
12. Fein DAet al. Pretreatment hemoglobin level influences local control and survival of T1−T2 squamous cell carcinoma of the glottic larynx.J Clin Oncol 1995;13: 2077–2083.
13. Moldawer LLet al. Cachectin/tumor necrosis, factor-α alters red blood cell kinetics and induces anemiain vivo.FASEB J 1989;3: 1637–1643.
14. Honda Ket al. Anemia-inducing substance from plasma of patients with advanced malignant neoplasms.Cancer Res 1995;55: 3623–3628
15. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease.Blood 1992;80: 1639–1647.
16. Thatcher N. Controlled study of the efficacy and safety of recombinant human erythropoietin (Epoetin alpha: Cilag) in the prevention of anaemia in patients with small cell lung cancer receiving chemotherapy.Ann Oncol 1994;5 (Suppl 8): 89.
17. Rossof AH, Slayton RE, Perlia CP. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NCS 119875, CACP).Cancer 1972;30: 1451–1456. DOI: 10.1002/1097-0142(197212)30:6<1451::AID-CNCR2820300606>3.0.CO;2-Q
18. Wiltshaw E, Kroner T. Phase II study of cis-dichlorodiammineplatinum (II) (NSC-199875) in advanced adenocarcinoma of the ovary.Cancer Treat Rep 1976;60: 55–60.
19. Gamucci Tet al. Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin.Eur J Cancer 1993;29A (Suppl2): 13–14. DOI: 10.1016/S0959-8049(05)80283-7
20. Okamoto Het al. Chemotherapy-induced anemia in patients with primary lung cance.Ann Oncol 1992;3: 819–824.
21. de Campos Eet al. Clinical andin vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.J Clin Oncol 1995;13: 1623–1631.
22. Wood PA, Hrushesky JM. Cisplatin-associated anemia: an erythropoietin deficiency syndrome.J Clin Invest 1995;95: 1650–1659. DOI: 10.1172/JCI117840
23. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies.Semin Oncol 1994;21 (Suppl 3): 21–28.
24. Ludwig Het al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.Cancer 1995;76: 2319–2329. DOI: 10.1002/1097-0142(19951201)76:11<2319::AID-CNCR2820761121>3.0.CO;2-U
25. Voigtmann Ret al. rhEPO in the treatment of anemia associated with malignancy. In: Smyth JF, Boogaerts MA, Ehmer BRM (eds).rhErythropoietin in Cancer Supportive Treatment, Marcels Dekker: New York, 1996, pp 113–127.
26. Leitgeb Cet al. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.Cancer 1994;73: 2532–2542. DOI: 10.1002/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5
27. Glaspy Jet al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice.J Clin Oncol 1997;15: 1218–1234.
28. Cazzola Met al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: Dose finding and identification of predictors of response.Blood 1995;86: 4446–4453.
29. Österborg Aet al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma—A randomized multicenter study.Blood 1996;87: 2675–2682.
30. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoetin-a) therapy in cancer patients.Blood 1995;85: 1676–1678.
31. Del Mastro Let al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia.J Clin Oncol 1997;15: 2715–2721.
32. ten Bokkel Huinink Wet al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian cancer treated with platinum-based chemotherapy.Med Oncol 1998;15: 174–182.